Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 3/20 | 0.42 |
| ▸ | RAB9A | P51151 | 3/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | CES2 | O00748 | 2/20 | 0.42 |
| ▸ | CES1 | P23141 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | KIF11 | P52732 | 3/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29229419 | 1.00 | ALDH1A1 (0.46) | ALDH1A1SMN1; SMN2TSHRGAANPC1 | |
| SCHEMBL31097913 | 1.00 | ALDH1A1 (0.46) | ALDH1A1SMN1; SMN2TSHRGAANPC1 | |
| SCHEMBL2695436 | 1.00 | ALDH1A1 (0.46) | ALDH1A1SMN1; SMN2TSHRGAANPC1 | |
| SCHEMBL2696567 | 1.00 | ALDH1A1 (0.46) | ALDH1A1SMN1; SMN2TSHRGAANPC1 | |
| Water SCHEMBL6653863 | 0.98 | ALDH1A1 (0.44) | ALDH1A1SMN1; SMN2TSHRGAANPC1 | |
| SCHEMBL27510642 | 0.90 | ALDH1A1 (0.41) | ALDH1A1SMN1; SMN2TSHRGAANPC1 | |
| SCHEMBL3615410 | 0.87 | CA2 (0.48) | ALDH1A1SMN1; SMN2TSHRNPC1RAB9A | |
| SCHEMBL71815 | 0.81 | CYP2C9 (0.61) | ALDH1A1SMN1; SMN2TSHRGAANPC1 | |
| SCHEMBL11529757 | 0.81 | ALDH1A1 (0.46) | ALDH1A1SMN1; SMN2TSHRGAANPC1 | |
| SCHEMBL2207056 | 0.81 | ALDH1A1 (0.46) | ALDH1A1SMN1; SMN2TSHRGAANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 435 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250230160-A1 | PROCESS FOR THE PREPARATION OF 4-((6BR,10AS)-3-METHYL-2,3,6B,9,10,10A-HEXAHYDRO-1H,7H-PYRIDO[3',4':4,5]PYRROLO[1,2,3-DE]QUINOXALIN-8-YL)-1-(4-FLUORO-PHENYL)-BUTAN-1-ONE AND INTERMEDIATES THEREOF | MSN LABORATORIES PRIVATE LIMITED, R&D CENTER (IN) | 2025-07-17 | — | — | US | claimed |
| CN-118702588-A | Preparation method of ilast and intermediate thereof | 重庆华邦胜凯制药有限公司 | 2024-09-27 | — | — | CN | claimed |
| CN-118420658-B | Preparation method of chiral triazine compound | 天津辰欣药物研究有限公司 | 2024-09-20 | — | — | CN | claimed |
| CN-118420658-A | Preparation method of chiral triazine compound | 天津辰欣药物研究有限公司 | 2024-08-02 | — | — | CN | claimed |
| CN-114698375-B | Process for preparing 2-cyanoethyl (4S) -4- (4-cyano-2-methoxyphenyl) -5-ethoxy-2, 8-dimethyl-1, 4-dihydro-1, 6-naphthyridine-3-carboxylate | 拜耳公司 | 2024-08-02 | — | — | CN | claimed |
| US-20240199599-A1 | PROCESS FOR THE PREPARATION OF 2-CYANOETHYL (4S)-4-(4-CYANO-2-METHOXY-PHENYL)-5-ETHOXY-2,8-DIMETHYL-1,4-DIHYDRO-1,6-NAPHTHYRIDINE-3-CARBOXYLATE BY RESOLUTION OF RACEMATES BY MEANS OF DIASTEREOMERIC TARTARIC ACID ESTERS | BAYER AKTIENGESELLSCHAFT (DE) | 2024-06-20 | — | — | US | claimed |
| EP-3122708-B1 | AN IMPROVED PROCESS FOR THE PREPARATION OF EXAMETAZIME | JUBILANT GENERICS LTD (IN) | 2024-06-12 | — | — | EP | claimed |
| CN-117964625-A | Preparation method of high-optical-purity ponatinib intermediate | 安徽万邦医药科技股份有限公司 | 2024-05-03 | — | — | CN | claimed |
| WO-2023195027-A1 | PROCESS FOR THE PREPARATION OF 4-((6BR,10AS)-3-METHYL-2,3,6B,9,10,10A-HEXAHYDRO-1H,7H-PYRIDO[3',4':4,5]PYRROLO[1,2,3-DE]QUINOXALIN-8-YL)-1-(4-FLUORO-PHENYL)-BUTAN-1-ONE AND INTERMEDIATES THEREOF | MSN LABORATORIES PRIVATE LIMITED, R&D CENTER (IN) | 2023-10-12 | — | — | WO | claimed |
| WO-2022157633-A1 | ENANTIOMERICALLY PURE DESGLYMIDODRINE AND PROCESS FOR PREPARATION THEREOF | CADILA HEALTHCARE LIMITED (IN) | 2022-07-28 | — | — | WO | claimed |
| US-7109353-B2 | Process for preparing 5,6-dihydro-4-(S)-(ethylamino)-6-(S) methyl-4H-thieno[2,3b]thiopyran-2-sulphonamide-7,7-dioxide HCl | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2006-09-19 | — | — | US | claimed |
| US-20060142595-A1 | Process for preparing 5,6-dihydro-4-(S)-(ethylamino)-6-(S) methyl-4H-thieno[2,3b]thiopyran-2-sulphonamide-7,7-dioxide HCI | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH | 2006-06-29 | — | — | US | claimed |
| CN-1575282-A | Lactam compound | LILLY CO ELI (US) | 2005-02-02 | — | — | CN | claimed |
| US-20040248878-A1 | Lactam compound | KOENIG THOMAS MITCHELL (US) | 2004-12-09 | — | — | US | claimed |
| EP-1353910-A2 | LACTAM COMPOUND | ELI LILLY AND COMPANY (US) | 2003-10-22 | — | — | EP | claimed |
| WO-2002040451-A2 | LACTAM COMPOUND | ELI LILLY AND COMPANY (US) | 2002-05-23 | — | — | WO | claimed |
| US-5948487-A | Anisotropic retardation layers for display devices | 3M INNOVATIVE PROPERTIES COMPANY (US) | 1999-09-07 | — | — | US | claimed |
| EP-0530335-B1 | DIPHOSPHONIC ACID DERIVATES AS INTERMEDIATES FOR THE PRODUCTION OF DIPHOSPHINE LIGANDS | HOFFMANN LA ROCHE (CH) | 1996-08-14 | — | — | EP | claimed |
| US-5326782-A | Salts derived from 26-(dialkylaminoalkylsulphonyl)pristinamycin IIB | RHONE-POULENC RORER S.A. (FR) | 1994-07-05 | — | — | US | claimed |
| US-4458084-A | Cyclopentene derivatives | THE UPJOHN COMPANY (US) | 1984-07-03 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250230160-A1 | PROCESS FOR THE PREPARATION OF 4-((6BR,10AS)-3-METHYL-2,3,6B,9,10,10A-HEXAHYDRO-1H,7H-PYRIDO[3',4':4,5]PYRROLO[1,2,3-DE]QUINOXALIN-8-YL)-1-(4-FLUORO-PHENYL)-BUTAN-1-ONE AND INTERMEDIATES THEREOF | CYP1B1, CYP4B1, CYP7A1 | ALDH1A1 116/4885SMN1; SMN2 1382/4885TSHR 2488/4885 |
| US-20040248878-A1 | Lactam compound | AAAS, CHLSN, APH1B | ALDH1A1 1677/4885SMN1; SMN2 2842/4885TSHR 4757/4885 |
| US-20060142595-A1 | Process for preparing 5,6-dihydro-4-(S)-(ethylamino)-6-(S) methyl-4H-thieno[2,3b]thiopyran-2-sulphonamide-7,7-dioxide HCI | CA7, CYP3A7, CA2 | ALDH1A1 1072/4885SMN1; SMN2 3053/4885TSHR 1823/4885 |
| US-20240199599-A1 | PROCESS FOR THE PREPARATION OF 2-CYANOETHYL (4S)-4-(4-CYANO-2-METHOXY-PHENYL)-5-ETHOXY-2,8-DIMETHYL-1,4-DIHYDRO-1,6-NAPHTHYRIDINE-3-CARBOXYLATE BY RESOLUTION OF RACEMATES BY MEANS OF DIASTEREOMERIC TARTARIC ACID ESTERS | MVD, VARS1, CYP4B1 | ALDH1A1 1009/4885SMN1; SMN2 3272/4885TSHR 1322/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.